---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-042215"
form_type: "8-K"
ticker: "PTPI"
cik: "0001815903"
company_name: "Petros Pharmaceuticals, Inc."
filed_at: "2022-04-04T23:59:59+00:00"
generated_at: "2026-06-26T09:52:57.305579+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Petros Pharma reports 2021 net sales $7.8M, net loss down 56% to $9.0M

## Summary
- Net sales $7.8M vs $9.6M in 2020; prescription sales fell to $4.6M due to competitive coupons.
- Gross profit up 13% to $6.2M on lower write-offs and fulfillment costs; SG&A flat at $15.6M.
- Net loss improved to $9.0M from $20.6M, largely from reduced fair value derivative liability.
- Cash at year-end ~$24M; pursuing OTC switch for STENDRA with two self-selection studies launched.
- Collaboration with Dr. Drew Pinsky to raise men's health awareness; H100 Peyronie's license expanded.

## SEC filing metadata
- accession: 0001104659-22-042215
- form_type: 8-K
- ticker: PTPI
- cik: 0001815903
- company_name: Petros Pharmaceuticals, Inc.
- filed_at: 2022-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815903/000110465922042215/0001104659-22-042215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815903/000110465922042215/tm2211512d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-042215
- JSON: https://secwatch.observer/filing/0001104659-22-042215.json
- Plain text: https://secwatch.observer/filing/0001104659-22-042215.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.